ISRCTN14968657Completed未知
The Second Heart Program: a peer-focused, multidisciplinary harm reduction intervention to improve outcomes for people who inject drugs after admission for infective endocarditis
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- McMaster University
- Enrollment
- 40
Study Overview
Brief Summary
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34710094/ (added 29/10/2021)
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Age 18 or older
- •2. Able to provide informed consent in English
- •3. Admitted to either St Joseph’s Hospital or Hamilton General Hospital located in Hamilton with the diagnosis of infective endocarditis at the time of recruitment
- •4. History of injection drug use within 3 months of recruitment
Exclusion Criteria
- •1. Does not live in the City of Hamilton
Investigators
Similar Trials
Completed
Phase 2
A Dehydroepiandrosterone and Pharmacokinetics in Trauma study (ADaPT)Severe trauma injuryInjury, Occupational Diseases, PoisoningInjuries to unspecified part of trunk, limb or body regionISRCTN12961998niversity Hospitals Birmingham NHS Foundation Trust68
Active, not recruiting
Not Applicable
PROvision of braces for Patients with knee OsteoArthritis (PROP OA): a randomised controlled trialKnee osteoarthritis (symptomatic)Musculoskeletal DiseasesGonarthrosis [arthrosis of knee]ISRCTN28555470Keele University466
Completed
Phase 1
BUTEO: a clinical trial of BTT1023 in patients with primary sclerosing cholangitis (PSC)CholangitisPrimary sclerosing cholangitisISRCTN11233255niversity of Birmingham23
Active, not recruiting
Not Applicable
A pilot study to evaluate automatic deep vein thrombosis diagnostic softwareDeep vein thrombosisCirculatory SystemPhlebitis and thrombophlebitis of other deep vessels of lower extremitiesISRCTN11069056Oxford University Hospitals NHS Trust400
Active, not recruiting
Phase 2
Radiotherapy combined with immunotherapy in metastatic non-small cell lung cancer patientsAdvanced non-small cell lung cancer, stage IVMalignant neoplasm the lung, non-small cell lung cancerCancerISRCTN49817477Maastricht University88